

# Aging Population, Increasing Incidence Rates to boost the Global Colorectal Cancer Therapeutics Market Demand; says TNR

*Global Colorectal Cancer Therapeutics Market to Reach US\$ 27.8 Bn by 2031; Anticipated to Experience CAGR of 4.2% during 2023 – 2031*

WILMINGTON, DELAWARE, UNITED STATES, December 4, 2023

/EINPresswire.com/ -- Colorectal cancer

therapeutics refers to the diverse medical approaches used to manage and treat cancers occurring in the

colon or rectum. These strategies include surgical procedures, chemotherapy, radiation therapy, targeted medications, and immunotherapy. The selection of treatment methods depends on factors such as the cancer's stage, the patient's overall health, and the tumor's unique characteristics.



Read Full Report: [Global Colorectal Cancer Therapeutics Market Study](#)

## Global Colorectal Cancer Therapeutics Market Growth Drivers

**Aging Population and Increasing Incidence Rates:** The global aging population is contributing significantly to the demand for colorectal cancer therapeutics market. As people age, their risk to develop colorectal cancer is also increases. In many countries, the elderly population is expanding rapidly. For example, in the US, it is estimated that by 2030, the number of adults aged 65 and older will reach 72 million. This demographic shift is driving a higher incidence of colorectal cancer cases, necessitating a greater need for effective therapeutics and treatment options.

**Rising Awareness and Screening Efforts:** There is a growing emphasis on colorectal cancer screening and awareness campaigns worldwide. Many countries have implemented screening programs to detect the disease at earlier stages, leading to more successful treatment outcomes. For instance, in the United States, the percentage of adults aged 50 and older who reported being up-to-date with colorectal cancer screening increased from over 52% in 2002 to over 70% in 2021. Increased awareness and early detection efforts are driving demand for therapeutics, as early-stage cancers are often more treatable, further propelling market growth.

## Which Drug Class Will Have the Highest Share in the Global Colorectal Cancer Therapeutics Market in the Upcoming Years?

The immunotherapy segment dominated the global colorectal cancer therapeutics market by type in 2022. The dominance can be attributed to its transformative impact on treatment outcomes. Immunotherapy, particularly immune checkpoint inhibitors, has shown remarkable efficacy in treating advanced colorectal cancer cases. For instance, clinical trials have demonstrated that pembrolizumab, when used in specific patient populations, can lead to significant tumor response rates. Additionally, colorectal cancer patients with certain genetic mutations, like microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, have responded exceptionally well to immunotherapies. As a result, the increasing adoption of immunotherapy represents a major shift in the treatment paradigm, offering renewed hope for patients with advanced colorectal cancer.

### [View Our Press Release](#)

## Based on the Cancer Type Segment, Which is the Fastest Growing Segment in the Global Colorectal Cancer Therapeutics Market during the Forecast Period?

Among cancer types, gastrointestinal carcinoid tumors segment is anticipated to be the fastest growing segment in the global colorectal cancer therapeutics market during the forecast period. The growth is driven by their increasing recognition and diagnosis. While representing a smaller proportion of colorectal cancers, their incidence is rising. For example, the annual incidence of carcinoid tumors has been estimated at 0.6 cases per 100,000 individuals in the US. As medical imaging and diagnostic techniques have improved, more of these tumors are being detected. Furthermore, targeted therapies like somatostatin analogs and everolimus have demonstrated efficacy in managing gastrointestinal carcinoid tumors. This growing focus on specialized treatments for this subset is propelling its rapid growth within the broader colorectal cancer therapeutics market.

## Based on Regions, Which Region had the Highest Share in the Colorectal Cancer Therapeutics Market in 2022?

North America dominated the colorectal cancer therapeutics market in 2022. The region benefits from advanced healthcare infrastructure and access to cutting-edge treatment options, making it a hub for colorectal cancer research and development. Moreover, North America faces a relatively high incidence of colorectal cancer, with over 147,000 new cases reported annually in the US alone. This prevalence underscores the need for effective therapeutics. Additionally, strong government support for cancer research, coupled with collaborations between academic institutions and pharmaceutical companies, further solidifies North America's position as a leader in colorectal cancer therapeutics innovation and accessibility.

### [View Our Blog](#)

## Global Colorectal Cancer Therapeutics Market Key Participants

- o Amgen Inc.

- o Bayer AG
- o Bristol-Myers Squibb Belgium SA/NV
- o F. Hoffmann-La Roche Ltd
- o Lilly
- o Merck & Co., Inc.
- o Novartis AG
- o Pfizer Inc.
- o Regeneron Pharmaceuticals Inc.
- o Sanofi
- o Other market participants

## Global Colorectal Cancer Therapeutics Market

### By Drug Class

- o Chemotherapy
- o Immunotherapy
- o Targeted Therapy
- o Others

### By Cancer Type

- o Colorectal Adenocarcinoma
- o Gastrointestinal Carcinoid Tumors
- o Others

### By Distribution Channel

- o Hospital Pharmacies
- o Retail Pharmacies
- o Online Pharmacies
- o Others

### By Region

- o North America (U.S., Canada, Mexico, Rest of North America)
- o Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- o Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- o Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- o Latin America (Brazil, Argentina, Rest of Latin America)

### Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

United Kingdom: +44 753-710-5080  
United States: +1 302-232-5106  
Email: [askanexpert@thenicherresearch.com](mailto:askanexpert@thenicherresearch.com)  
Website: [www.thenicherresearch.com](http://www.thenicherresearch.com)

Jay Reynolds  
The Niche Research  
302-232-5106  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/672781727>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.